Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOP PNET 5 medulloblastoma
NL-OMON59234Phase 3Recruiting
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Sep 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lomustine and carboplatin in medulloblastoma and medulloblastoma WNT activated (WNT-MB) (5 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Event-free survival. Started Sep 2024; status: recruiting.
02
Drugs
lomustinecarboplatin
03
Conditions
medulloblastomamedulloblastoma WNT activated (WNT-MB)
Beyond the preview
Go deeper on NL-OMON59234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59234.